Zhejiang Hisun Pharmaceutical Co., Ltd.

600267

CNE0000013Z2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
7.9 ^CNY	+3.40%		+6.76%	-15.60%

Apr. 20	Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	CI
Apr. 18	Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million.	CI

Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 22, 2022.

September 20, 2023

From July 1, 2023 to September 20, 2023, the company has repurchased 7,669,100 shares, representing 0.64% for CNY 81.02 million. With this, the company has completed the repurchase of 18,489,100 shares, representing 1.55% for CNY 194.73 million under the buyback announced on September 22, 2022.

Latest news about Zhejiang Hisun Pharmaceutical Co., Ltd.

Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Apr. 19	CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million.	Apr. 17	CI
Hisun Pharma's Unit Gets Nod for Pig Vaccine	Apr. 17	MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Apr. 01	CI
China Energy Engineering Issues Apology Over Former Director's Stake Disposal Breaches	Mar. 27	MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Jan. 02	CI
Zhejiang Hisun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Dec. 22	CI
Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Dec. 21	CI
Gogox Holdings Chairman Steps Down	Dec. 18	MT
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug from Pfizer	Dec. 15	MT
Hisun Pharmaceutical CFO Resigns	Nov. 30	MT
Hisun Pharmaceutical's Unit Gets Import Drug Certificate for Methylprednisolone Tablets	Nov. 29	MT
Hisun Pharmaceutical's Unit Gets Nod for Carprofen Tablets for Dogs	Nov. 29	MT
Hisun Pharma Registers New Veterinary Drug	Nov. 09	MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Hisun Pharmaceutical Gets China Nod to Market Cytarabine	23-10-11	MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 22, 2022.	23-09-20	CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 22, 2022, has closed with 18,489,100 shares, representing 1.55% for CNY 194.73 million.	23-09-19	CI
Zhejiang Hisun Pharmaceutical Co., Ltd.(XSSC:600267) added to S&P Global BMI Index	23-09-18	CI
Zhejiang Hisun Pharmaceutical Co., Ltd.(XSSC:600267) added to FTSE All-World Index	23-09-18	CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	23-09-14	MT
Hisun Pharma Unit Gets Nod to Produce Apremilast API	23-09-05	MT
Hisun Pharma Chairman, Vice Chairman Resign	23-09-01	MT
Hisun Biomaterials Chairman Resigns	23-09-01	MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI

Chart Zhejiang Hisun Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Hisun Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.9 CNY

Average target price

7.4 CNY

Spread / Average Target

-6.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.	-15.60%	1.25B
ELI LILLY AND COMPANY	+25.81%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.69%	352B
MERCK & CO., INC.	+18.81%	332B
ABBVIE INC.	+3.37%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.32%	145B

Other Pharmaceuticals

Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities

600267

CNE0000013Z2

Pharmaceuticals

Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 22, 2022.

Latest news about Zhejiang Hisun Pharmaceutical Co., Ltd.

Chart Zhejiang Hisun Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals